We are identified as one of the leading organizations, engaged in offering Natdac Tablets. Our expert agents procure these tablets from the certified vendors of the market. The tablets are indicated in combination with sofosbuvir for the treatment of a patient with chronic hepatitis C virus. Natdac 60 mg Tablet are recommended to be taken orally with or without meals. We offer these tablets at pocket-friendly prices.
Natdac Tablets Exporters & suppliers
Natdac Tablets Features:
- Effective antiviral drugs
- Taken orally
- Longer shelf life
Natdac Tablets Product Description
Natdac 60 tablets is an inhibitor of non-structural protein 5A (NS5A).
Each film-coated tablet contains Daclatasvir equivalent to Daclatasvir 30 mg or 60 mg.
NATDAC INDICATIONS AND USAGE
Natdac 60 mg tablets is indicated in combination with Sofosbuvir for the treatment of patient with chronic hepatitis C virus (HCV) genotype 3 infection.
NATDAC TABLETS DOSAGE
Treatment with Natdac 60 should be initiated and monitored by a physician experienced in the management of chronic hepatitis C. The recommended dose of Natdac 60 is 60 mg once daily to be taken orally with or without meals. MyDacla 60 must be administered in combination with other medical products. The Packages inserts of the medicinal products in the regimen should also be consulted before initiation of therapy with Natdac 60. Recommended regimens and treatment duration are provided below.
Dose modification, interruption, and discontinuation
Dose modification of Natdac 60 mg tablets to manage adverse reactions is not recommended.
Advantages of Natdac 60 mg tablets
- They have high tolerability and have a high safety profile
- Superior efficacy in hepatitis C genotype 3
- Offer the shortest treatment no matter what genotype the patient is suffering from
- Recommended by EASL and FDA approved
Side effects of Natdac tablets 60 mg
- A headache
- Shortness of breath
- Chest pain
Warnings and precautions:
Natdac is not administered as monotherapy. Instead, they are administered in combination with other medicinal products to cure HCV infection.
Also, the safety and efficacy of this tablet in combination with Daclatasvir and sofosbuvir is evaluated within the limited number of patients.
It decompensates the liver: The efficacy and safety of MyDekla, which is used in treating HCV infection in patients, have not been established.
Pregnancy and contraception: It should not be used during pregnancy or in women who are having a problem in conceiving.